Table 1 Clinical characteristics of the studied cohort.
From: Enhanced inflammation and suppressed adaptive immunity in COVID-19 with prolonged RNA shedding
Baseline characteristic | Non-COVID-19 | COVID-19 SC | COVID-19 LC |
|---|---|---|---|
(N = 35) | (N = 19) | (N = 19) | |
Gender—no.a(%) | |||
Male | 18 (51.4) | 9 (47.4) | 10 (52.6) |
Female | 17 (48.6) | 10 (52.6) | 9 (47.4) |
Age—yrb | |||
Mean ± SD | 43.1 ± 18.3 | 42.9 ± 12.5 | 51.5 ± 11.5 |
Median (IQR) | 37.0 | 44 | 51 |
(28.5–56.0) | (33.0–50.0) | (44.5–56.0) | |
Range | 18–80 | 20–67 | 33–84 |
Symptoms—no. (%) | |||
Fever | 29 (82.9) | 10 (57.8) | 13 (68.4) |
Cough | 2 (5.7) | 13 (73.7) | 17 (89.5) |
Diarrhea | 1 (2.9) | 11 (63.2) | 8 (42.1) |
Fatigue | 1 (2.9) | 8 (47.4) | 8 (42.1) |
Comorbidities—no. (%) | |||
Hypertension | 3 (15.8) | 6 (31.6) | |
Diabetes | 1 (5.3) | 3 (15.8) | |
Hepatitis B | 2 (10.5) | 0 (0.0) | |
Coronary sclerosis | 1 (5.3) | 3 (15.8) | |
Gastrohelcosis | 1 (5.3) | 0 (0.0) | |
Psoatic strain | 0 (0.0) | 1 (5.3) | |
Chronic gynecologic inflammation | 1 (5.3) | 0 (0.0) | |
Gout | 0 (0.0) | 1 (5.3) | |
Asthma | 0 (0.0) | 1 (5.3) | |
Chronic renal failure | 1 (5.3) | 0 (0.0) | |
Treatment—no. (%) | |||
Lopinavir and ritonavir | 19 (100.0) | 19 (100.0) | |
Atomized interferon | 19 (100.0) | 19 (100.0) | |
Arbidol | 7 (36.8) | 12 (63.2) | |
Lianhuaqingwen (Chinese traditional medicine) | 16 (84.2) | 17 (89.5) | |
Ribavirin | 0 (0.0) | 3 (15.8) | |
Hydroxychloroquine | 1 (5.3) | 3 (15.8) | |
